The University of Lodz, Poland, will invest in Cellectricon’s Cellaxess®HT. The university plans to use the product for its research program focusing on cell biology and molecular genetics of clinically relevant genes related to cancer treatment.
Cellaxess®HT is a fully automated workstation for high-throughput transfection. The system enables reagent-free delivery of siRNA and cDNA to a range of primary cells and cell lines.